Is double coverage of gram-negative organisms necessary? (Q43453146)

23 November 2017

Is double coverage of gram-negative organisms necessary? (English)

1 reference

23 November 2017

Gram-negative bacteria

0 references

author name string

Sarah J Johnson

series ordinal

1

1 reference

PubMed ID

21200057

23 November 2017

Erika J Ernst

series ordinal

2

1 reference

PubMed ID

21200057

23 November 2017

Kevin G Moores

series ordinal

3

1 reference

23 November 2017

1 January 2011

1 reference

American Journal of Health-System Pharmacy

23 November 2017

1 reference

23 November 2017

68

1 reference

23 November 2017

2

1 reference

23 November 2017

119-124

1 reference

Overview of nosocomial infections caused by gram-negative bacilli

23 November 2017

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Health care-associated pneumonia and community-acquired pneumonia: a single-center experience

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Antimicrobial agent therapy for Pseudomonas aeruginosa

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Ciprofloxacin vs an aminoglycoside in combination with a beta-lactam for the treatment of febrile neutropenia: a meta-analysis of randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Beta-lactam and fluoroquinolone combination antibiotic therapy for bacteremia caused by gram-negative bacilli

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Piperacillin/tazobactam plus ceftazidime versus sulbactam/ampicillin plus aztreonam as empirical therapy for fever in severely neutropenic pediatric patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Piperacillin plus aztreonam for treatment of neutropenic fever

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Therapeutic efficacy of the combination of aztreonam with cefotaxime in the treatment of severe nosocomial pneumonia. Comparative study against amikacin combined with cefotaxime

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

New beta-lactams: new problems for the internist

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Empirical antibiotic choice for the seriously ill patient: are minimization of selection of resistant organisms and maximization of individual outcome mutually exclusive?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Epidemiology of invasive candidiasis: a persistent public health problem

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

Attributable mortality of nosocomial candidemia, revisited

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090360

31 March 2020

Identifiers

DOI

10.2146/AJHP090360

1 reference

23 November 2017

1 reference

PubMed ID

21200057